Zoran Antonijevic

481 total citations
18 papers, 296 citations indexed

About

Zoran Antonijevic is a scholar working on Economics and Econometrics, Statistics and Probability and Statistics, Probability and Uncertainty. According to data from OpenAlex, Zoran Antonijevic has authored 18 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Economics and Econometrics, 13 papers in Statistics and Probability and 5 papers in Statistics, Probability and Uncertainty. Recurrent topics in Zoran Antonijevic's work include Statistical Methods in Clinical Trials (13 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Meta-analysis and systematic reviews (5 papers). Zoran Antonijevic is often cited by papers focused on Statistical Methods in Clinical Trials (13 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Meta-analysis and systematic reviews (5 papers). Zoran Antonijevic collaborates with scholars based in United States, United Kingdom and Sweden. Zoran Antonijevic's co-authors include Rasika Kalamegham, Robert A. Beckman, José Paulo Pinheiro, Roger Lewis, Shuai Yuan, Xiaoyun Li, Cong Chen, Natasa Rajicic, Nitin R. Patel and Sandeep Menon and has published in prestigious journals such as PLoS ONE, Nature Reviews Drug Discovery and Statistics in Medicine.

In The Last Decade

Zoran Antonijevic

18 papers receiving 269 citations

Peers

Countries citing papers authored by Zoran Antonijevic

Since Specialization

Citations

This map shows the geographic impact of Zoran Antonijevic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zoran Antonijevic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zoran Antonijevic more than expected).

Fields of papers citing papers by Zoran Antonijevic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zoran Antonijevic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zoran Antonijevic. The network helps show where Zoran Antonijevic may publish in the future.

Co-authorship network of co-authors of Zoran Antonijevic

This figure shows the co-authorship network connecting the top 25 collaborators of Zoran Antonijevic. A scholar is included among the top collaborators of Zoran Antonijevic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zoran Antonijevic. Zoran Antonijevic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Aiding the Adoption of Master Protocols by Optimizing Patient Engagement 2023 ·Therapeutic Innovation & Regulatory Science ·(unknown), Deborah Collyar, Zoran Antonijevic, Robert A. Beckman, Ruben G.W. Quek, Jingjing Ye	1
2	A framework for assessing the impact of accelerated approval 2022 ·PLoS ONE ·A. Lawrence Gould, R. Keith Campbell, John W. Loewy, Robert A. Beckman, Jyotirmoy Dey, Anja Schiel, Carl‐Fredrik Burman, Joey Tianyi Zhou, Zoran Antonijevic, (unknown), Rui Tang	4
3	Innovations in Clinical Development in Rare Diseases of Children and Adults: Small Populations and/or Small Patients 2022 ·Pediatric Drugs ·Robert A. Beckman, Zoran Antonijevic, Mercedeh Ghadessi, Heng Xu, Cong Chen, (unknown), Rui Tang	3
4	Advancing innovative clinical trials to efficiently deliver medicines to patients 2022 ·Nature Reviews Drug Discovery ·Robert A. Beckman, Fanni Natanegara, Pritibha Singh, (unknown), Zoran Antonijevic, Yi Liu, Cristiana Mayer, Karen N. Price, Rui Tang, (unknown), (unknown), Courtney A. Granville, (unknown)	12
5	Planning for the Next Pandemic: Ethics and Innovation Today for Improved Clinical Trials Tomorrow 2021 ·Statistics in Biopharmaceutical Research ·(unknown), Cristiana Mayer, Rui Tang, (unknown), Lisa M. LaVange, Zoran Antonijevic, Robert A. Beckman	6
6	Efficient two-stage sequential arrays of proof of concept studies for pharmaceutical portfolios 2020 ·Statistical Methods in Medical Research ·(unknown), (unknown), Zoran Antonijevic, Martin Posch, Valeriy R. Korostyshevskiy, Robert A. Beckman	2
7	The Impact of Adaptive Design on Portfolio Optimization 2016 ·Therapeutic Innovation & Regulatory Science ·Zoran Antonijevic	7
8	PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms 2016 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Zoran Antonijevic, (unknown), (unknown), (unknown), (unknown), John W. Loewy, Denis Lacombe, Subha Madhavan, (unknown), L. Esserman	27
9	Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study 2016 ·Statistics in Biopharmaceutical Research ·Cong Chen, Xiaoyun Li, Shuai Yuan, Zoran Antonijevic, Rasika Kalamegham, Robert A. Beckman	39
10	Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker 2016 ·Clinical Pharmacology & Therapeutics ·(unknown), Zoran Antonijevic, Rasika Kalamegham, (unknown)	47
11	Sample Size Re-estimation Designs In Confirmatory Clinical Trials—Current State, Statistical Considerations, and Practical Guidance 2015 ·Statistics in Biopharmaceutical Research ·Yili Pritchett, Sandeep Menon, (unknown), Zoran Antonijevic, (unknown), (unknown), (unknown), (unknown), (unknown)	22
12	Optimization of Pharmaceutical R&D Programs and Portfolios 2014 ·DIAL (Catholic University of Leuven) ·Zoran Antonijevic	12
13	Views on Emerging Issues Pertaining to Data Monitoring Committees for Adaptive Trials 2013 ·Therapeutic Innovation & Regulatory Science ·Zoran Antonijevic, Paul Gallo, Christy Chuang‐Stein, Vladimir Dragalin, John W. Loewy, Sandeep Menon, (unknown), Caroline Morgan, Matilde Sanchez	9
14	A Practical Guide to Data Monitoring Committees in Adaptive Trials 2013 ·Therapeutic Innovation & Regulatory Science ·(unknown), Paul Gallo, John W. Loewy, Sandeep Menon, Zoran Antonijevic, Jared Christensen, Christy Chuang‐Stein, (unknown)	9
15	Optimizing Drug Development Programs: Type 2 Diabetes Case Study 2013 ·Therapeutic Innovation & Regulatory Science ·Zoran Antonijevic, (unknown), (unknown), Carl‐Fredrik Burman, José Cirı́aco Pinheiro, Klas Bergenheim	11
16	A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk 2013 ·Statistics in Medicine ·Nitin R. Patel, (unknown), Zoran Antonijevic, Natasa Rajicic	25
17	Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase III 2010 ·Statistics in Biopharmaceutical Research ·Zoran Antonijevic, José Paulo Pinheiro, (unknown), Roger Lewis	33
18	Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies 2010 ·Statistics in Biopharmaceutical Research ·José Paulo Pinheiro, Frederic L. Sax, Zoran Antonijevic, Björn Bornkamp, Frank Bretz, Christy Chuang‐Stein, Vladimir Dragalin, (unknown), Paul Gallo, William R. Gillespie, Chyi‐Hung Hsu, Frank Miller, S. Krishna Padmanabhan, Nitin Patel, Inna Perevozskaya, Amit Roy, Ashish Sanil, (unknown)	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact